167 related articles for article (PubMed ID: 22083486)
21. Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies.
Goto N; Hara T; Tsurumi H; Ogawa K; Kitagawa J; Kanemura N; Kasahara S; Yamada T; Shimizu M; Nakamura M; Matsuura K; Moriwaki H
Am J Hematol; 2010 Nov; 85(11):872-6. PubMed ID: 20882524
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants.
Kawada M; Fukuoka N; Kondo M; Okazaki K; Kusaka T; Kawada K; Itoh S
Pediatr Infect Dis J; 2009 Sep; 28(9):840-2. PubMed ID: 19636279
[TBL] [Abstract][Full Text] [Related]
23. Micafungin Plasma Levels Are Not Affected by Continuous Renal Replacement Therapy: Experience in Critically Ill Patients.
Vossen MG; Knafl D; Haidinger M; Lemmerer R; Unger M; Pferschy S; Lamm W; Maier-Salamon A; Jäger W; Thalhammer F
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584142
[TBL] [Abstract][Full Text] [Related]
24. Intracellular concentrations of micafungin in different cellular compartments of the peripheral blood.
Farowski F; Cornely OA; Vehreschild JJ; Bauer T; Hartmann P; Steinbach A; Vehreschild MJ; Scheid C; Müller C
Int J Antimicrob Agents; 2012 Mar; 39(3):228-31. PubMed ID: 22230332
[TBL] [Abstract][Full Text] [Related]
25. Maintenance of therapeutic concentrations of micafungin administered 5 days/week in a leukemic adolescent with invasive candidiasis.
Castagnola E; Cangemi G; Barco S; Bandettini R; Dallorso S; Virga F; Dufour C
Clin Microbiol Infect; 2014 Nov; 20(11):O975-6. PubMed ID: 24621154
[No Abstract] [Full Text] [Related]
26. Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.
Autmizguine J; Hornik CP; Benjamin DK; Brouwer KL; Hupp SR; Cohen-Wolkowiez M; Watt KM
Pediatr Infect Dis J; 2016 Nov; 35(11):1204-1210. PubMed ID: 27314826
[TBL] [Abstract][Full Text] [Related]
27. [Why might micafungin be the drug of choice in pediatric patients?].
Ramos Amador JT; Prieto Tato L; Guillén Martín S
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():23-8. PubMed ID: 21420573
[TBL] [Abstract][Full Text] [Related]
28. Intraocular penetration of micafungin in patient with Candida albicans endophthalmitis.
Mochizuki K; Suemori S; Udo K; Komori S; Ohkusu K; Yamada N; Ogura S
J Ocul Pharmacol Ther; 2011 Oct; 27(5):531-3. PubMed ID: 21751880
[TBL] [Abstract][Full Text] [Related]
29. Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.
Andes DR; Reynolds DK; Van Wart SA; Lepak AJ; Kovanda LL; Bhavnani SM
Antimicrob Agents Chemother; 2013 Nov; 57(11):5714-6. PubMed ID: 23959319
[TBL] [Abstract][Full Text] [Related]
30. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
[TBL] [Abstract][Full Text] [Related]
31. Urinary micafungin levels are sufficient to treat urinary tract infections caused by Candida spp.
Grau S; Luque S; Echeverría-Esnal D; Sorlí L; Campillo N; Montero M; Álvarez Lerma F; Plasencia V; Horcajada JP
Int J Antimicrob Agents; 2016 Aug; 48(2):212-4. PubMed ID: 27424599
[TBL] [Abstract][Full Text] [Related]
32. Micafungin.
Bell SG
Neonatal Netw; 2011; 30(5):329-33. PubMed ID: 21846628
[No Abstract] [Full Text] [Related]
33. Pharmacokinetics of micafungin in patients undergoing allogeneic hematopoietic stem cell transplantation.
Oshima K; Kanda Y; Kako S; Ohno K; Kishino S; Kurokawa M
Transpl Infect Dis; 2013 Jun; 15(3):323-7. PubMed ID: 23578224
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic profile of micafungin when co-administered with amphotericin B in healthy male subjects.
Undre NA; Stevenson P; Wilbraham D
Int J Clin Pharmacol Ther; 2014 Mar; 52(3):237-44. PubMed ID: 24472403
[TBL] [Abstract][Full Text] [Related]
35. Reduced elimination clearance of micafungin in rats with cholestatic hyperbilirubinemia.
Konishi H; Fukushima K; Sudo M; Sumi M; Minouchi T; Iga I; Shibata N; Takada K; Yamaji A
Fundam Clin Pharmacol; 2010 Aug; 24(4):457-62. PubMed ID: 19845766
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of an elevated dosage of micafungin in premature neonates.
Smith PB; Walsh TJ; Hope W; Arrieta A; Takada A; Kovanda LL; Kearns GL; Kaufman D; Sawamoto T; Buell DN; Benjamin DK
Pediatr Infect Dis J; 2009 May; 28(5):412-5. PubMed ID: 19319022
[TBL] [Abstract][Full Text] [Related]
37. Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis.
Benjamin DK; Deville JG; Azie N; Kovanda L; Roy M; Wu C; Arrieta A
Pediatr Infect Dis J; 2013 Nov; 32(11):e419-25. PubMed ID: 23958810
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis.
Undre N; Stevenson P; Baraldi E
Eur J Drug Metab Pharmacokinet; 2012 Mar; 37(1):31-8. PubMed ID: 21956255
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.
Lepak AJ; Zhao M; Berkow EL; Lockhart SR; Andes DR
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584152
[No Abstract] [Full Text] [Related]
40. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
